1. On June 26, 2018, the Defendant’s disposition of non-approval of an additional injury or disease against the deceased A shall be revoked.

2. The costs of the lawsuit are assessed against the defendant.

1. Details of the disposition;

A. On October 3, 2015, A (C) entered into a stock company D and was in charge of loading and unloading goods from freezing vehicles. On August 23, 2016, A (C) performed freezing and loading and unloading work at freezing vehicles (hereinafter referred to as “bring-out and cerebral blood transfusion”) and received approval from the Defendant on March 13, 2017 for the period of medical care from August 23, 2016 to May 18, 2018, and provided medical care.

B. On November 12, 2016, A, who was under medical care due to an officially approved injury and disease, the cerebrovascular occurred, and on January 18, 2018, which had been under medical care due to the brain death and brain death, the cerebrscular occurred again on January 18, 2018.

Accordingly, on January 25, 2018, A submitted a medical treatment plan to the Defendant that he/she needs to be hospitalized in a middle-patient room and undergo brain pressure control and respiratory treatment. However, on March 28, 2018, the Defendant issued a disposition not to approve A’s medical treatment plan on the ground that “The recent part of cerebrovascular is different from the part of the cardioscular, and thus, is considered to be a new cerebrovascular irrelevant to the organ approved branch.”

C. On June 22, 2018, A filed a lawsuit seeking the revocation of a non-approval disposition of the above medical treatment plan under this court’s 2018Gudan65074, and this court rendered a judgment revoking the above medical treatment plan non-approval disposition on November 30, 2018.

Therefore, although the defendant appealed, the appellate court (Seoul High Court 2018Nu77984) dismissed the defendant's appeal on June 20, 2019.

(hereinafter referred to as "litigations for cancellation of non-approval of a medical plan").

On the other hand, on June 7, 2018, A filed a request for additional injury or disease with respect to “the instant injury or disease” (hereinafter referred to as “the instant injury or disease”) with respect to the Defendant, by the color fladism of the bovine spongiformiform encephalopathy, in detail known brain-resistant blood, brain-resistant cerebriform encephalopathy, brain-resistant cerebriform encephalopathy, and cerebriformiform encephalopathy under the cerebriformiform encephalopathy.

On June 26, 2018, the defendant against A on June 26, 2018, "the part of the blood transfusion of the previous approved injury and disease is brain low nuclear part, which was made by June 2018.